Special Situations
4年前
NIMU + Upd. Info.
* * *
NIMU
Non-Invasive Monitoring Systems, Inc.
#Share Structure.
A/S: 400,000,000
O/S: 154,810,655
Restricted O/S: 111,593,393
Unrestricted O/S: 43,217,262
Held at DTC: 39,948,758
https://www.otcmarkets.com/stock/NIMU/security
#Reporting Status.
U.S. Reporting: SEC Reporting
#Florida SOS.
Incorporated In: Florida
Florida SOS Status: INACTIVE
http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=NONINVASIVEMONITORINGSYSTEMS%206817062&aggregateId=domp-681706-93eecf7a-c32f-487c-b9b9-de40ae365acc&searchTerm=Non-Invasive%20Monitoring%20Systems&listNameOrder=NONINVASIVEMONITORINGSYSTEMS%206817062
#Plan of Operation.
"The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act)."
"The Company is assessing potential mergers, acquisitions and strategic collaborations."
"The Company is seeking potential mergers, acquisitions and strategic collaborations."
Form 10-Q (for the Quarterly Period ended October 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220023536/form10-q.htm
#NOL.
"At July 31, 2020, the Company had available Federal and State net operating loss carry forwards of approximately $16.9 million and foreign net operating loss carry forwards of approximately $0.1 million which expire in various years beginning in 2020."
Form 10-K (For the fiscal year ended July 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220020128/form10-k.htm
#Insider Ownership.
Dr. Phillip Frost
Common Stock: 54,690,325
Common Stock (%): 35.3%
Dr. Phillip Frost (Forbes).
https://www.forbes.com/profile/phillip-frost/
Dr. Phillip Frost (Bloomberg).
https://www.bloomberg.com/profile/person/1423894
Dr. Phillip Frost (Wikipedia).
https://en.wikipedia.org/wiki/Phillip_Frost
Jane H. Hsiao
Common Stock: 43,455,734
Common Stock (%): 28.1%
"Jane H. Hsiao, Ph.D., MBA. Dr. Hsiao has served as a Director and Chairman of the Board of Directors (the “Board”) of the Company since October 2008 and as Interim Chief Executive Officer since February 2012. Dr. Hsiao has served as Vice Chairman and Chief Technical Officer of OPKO Health, Inc. (NASDAQ GS:OPK), a specialty healthcare company, since May 2007 and as a director since February 2007. Dr. Hsiao is also a director of each of TransEnterix, Inc. (NYSE: TRXC), a medical device company. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing antiviral therapeutics for human diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006."
Form 10-K (For the fiscal year ended July 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220020128/form10-k.htm
Jane H. Hsiao (Forbes).
https://www.forbes.com/profile/jane-hsiao/
Jane H. Hsiao (Bloomberg).
https://www.bloomberg.com/profile/person/1455827
* * *
SittingPretty
6年前
Formalities covered, again lol different form label.
IRAFinancials ceo/founder/tax attorney Adam Bergman has been producing videos over this past year for thorough understanding of self directed IRAs and all IRA accounts.
It's becoming more popular in the investment arena, you can invest in stocks, real estate, precious metals, and much more through proper custodial accounts. I'm a client of several years and it's simply smart! Glad IRAFinancials is GOING PUBLIC!
SittingPretty
6年前
12/4/18 News Quote:
Bergman continued, “With over 50 million IRAs in the United States valued at over $9 trillion dollars and with an overall U.S. retirement industry valued at approximately $30 trillion dollars, we believe there are enormous organic and strategic growth opportunities in the self-directed retirement industry, especially with 10,000 baby boomers currently retiring each day and approximately $380 billion in IRA rollovers each year between 2012 and 2017.”
https://www.otcmarkets.com/stock/NIMU/news/story?e&id=1237244
About IRA Financial Group and IRA Financial Trust
IRA Financial Group is a growing financial technology provider of self-directed retirement plans as well as pension plan administrative services. IRA Financial Group has helped thousands of clients take back control over their retirement funds while gaining the ability to invest in almost any type of investment, including real estate, cryptocurrency, and private business investments. IRA Financial Trust is one of the leading IRA custodians that offers cryptocurrency investment options. IRA Financial Trust’s new mobile application allows its clients to establish a self-directed account, rollover funds, and initiate alternative asset investments all online or via smart phone.
SittingPretty
6年前
Growing provider of self-directed alternative asset retirement plans to go public through a reverse acquisition
Miami, FL , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Non-Invasive Monitoring Services, Inc. (OTCBB:NIMU.OB) (the “Company” or “NIMS”), IRA Financial Group LLC and IRA Financial Trust Company (collectively, “IRA Financial”) announced today that they have entered into an agreement to combine in a reverse acquisition transaction.
https://finance.yahoo.com/news/non-invasive-monitoring-systems-inc-135249922.html
investora2z
11年前
The 10K filed for the year ending July 31 reports $109,000 revenues compared to $250,000 for fiscal 2012. This large decrease primarily resulted from decrease in royalty revenues. The Exer-Rest platform unit sales for the 2013 fiscal year increased 57% over 2012, and the royalty revenue decreased due to decrease in product sales by SensorMedics. Importantly, SensorMedics indicated it will discontinue licensed product sales after current inventory is depleted. So the royalty revenue from SensorMedics is expected to be nearly zero. The total operating expenses in FY13 declined to $488,000 compared to $662,000 in FY12. The interest expense increased due to the borrowings under the $1 million revolving credit facility and $50,000 increase in notes payable. The company had $296,000 cash and positive working capital of approximately $47,000 as on July 31. The existing funds are likely to be sufficient to support its current operations in the United States and Canada through July 2014. This implies that the situation has worsened over the last few quarters and has reached a critical point. The stock is up 400% in 2013, and a large part of the move has come after investment made by Dr. Frost in April. So the positive movement is based primarily on the support of Dr. Frost. Frost's investments have done well recently, and he has also put in place some collaborations between his companies. His company Biozone Pharmaceuticals (BZNE), which owns a high potential drug delivery technology Qusomes, has got investments from two other companies OPKO Health (OPK) and MusclePharm (MSLP) where he has a stake. The technology is likely to help the two companies reduce production costs and improve efficacy of the drugs. For NIMU, however, the risk has increased significantly over the last few quarters. The main problem is that it is not likely to generate much revenues in the coming quarters.
investora2z
11年前
The stock has corrected nearly 33% from the 52 week high of $0.40 made in August. Despite this, the recent performance has been good as the stock has appreciated by more than 285% on a ytd basis. There have been some positive voices about the stock. One article on seekingalpha has recommended to buy the stock as the company seems to be reducing its losses over the past few years. It is important to note that the company does not have any meaningful revenues as of now, and it may take some time for the company to get going on that front. The stock has done great, and hence it is vulnerable to correction due to profit booking. Positive opinion about the stock is primarily based on the fact that Dr. Phillip Frost had taken a big stake in the company a few months ago. The average price of the acquisition in April was $0.05. That improved the sentiments dramatically, and investors are expecting good things going forward. Frost's investments have done well recently, and he is known to be an astute investor in the pharmaceuticals / biotech sector. His investment in Biozone Pharmaceuticals (BZNE) has made headlines recently. Biozone owns a high potential drug delivery technology Qusomes. According to the author, taking a position in NIMU could be part of a larger strategy of Dr. Frost, and OPKO Health (OPK) could be interested in the company. NIMU's product could complement and diversify OPKO's business. NIMU's product, which can help diagnose health problems just through external sensors without invasive diagnostic procedures, is believed to have a lot of potential. However, there are associated risks, and conversion of this potential into meaningful revenues may take some time. The recent selling by insiders also cannot be ignored. Meanwhile, the stock has already run up quite a bit over the last few months, effectively factoring a portion of the future positives.
investora2z
11年前
The stock has multiplied 6 times during the last nine months. The purchase of shares by Dr. Frost in April at $0.05 has led to significant improvement in sentiments. Fundamentally, the company does not have much to show right now, though a recent article on seekingalpha has expressed positive sentiments about it. The author believes that the company has reduced losses over the past few years, and its product has a lot of potential. Investment by Dr. Frost also points to the potential in the products, and also the possible synergies which NIMU can offer for the other companies where Dr. Frost has a stake. The article mentions that there may be some synergies with OPKO Health (OPK). Further, Dr. Frost is known to be great at picking companies with high potential when they are available at low valuations. He also looks for collaboration between his companies. For example, he has substantial stake in Biozone (BZNE) which owns a high potential drug delivery technology (QuSomes). There is an agreement between Biozone and OPKO Health (OPK) for testing of the QuSomes technology. Though the possibility of a stake by OPKO could be far fetched, it cannot be ruled out either. However, it is important to remember that the company hardly has any revenues right now, and it needs to show some improvement in the fundamentals to justify the recent jump in market cap. It has appreciated by 328% in 2013, and has multiplied 6 times from its 52 week low of $0.05. Presence of Dr. Frost is surely reassuring, but ultimately fundamentals may start to weigh down on the stock. So it may be good to be a bit cautious after such a huge run up. News flow and results of the next few quarters will determine whether the stock will be able to cross the recent highs.
rtraster
11年前
Next NIMU is BZNE by Dr Frost
I am not spamming here. Dr. Frost huge winner in Non-Invasive Monitoring Systems (NIMU), it doubled this year, hats off to everyone. His latest stock that has just started is BioZone (BZNE) check it out. Take a look at details, everything public in SEC filings. Dr. Frost and Opko Health are invested at $.20 with warrants at $.40 in BZNE. Almost exactly mirroring some of the investments that Dr Frost made in Non-Invasive Monitoring Systems.
Not spamming, NIMU has been a great Dr. Frost victory, beautifully done. BZNE rally has just started. Long with Dr. Frost, world's smartest pharma investor, building his next empire just like Ivax, billions to be made here.
He has made more than a billion dollars this year in Opko, check chart. Empire building. NIMU is a winner. BZNE is a winner.
madprophet
12年前
That would be a wild guess. Frost, Honig, and Brauser all invest in many companies alongside one another, but that doesn't mean a buyout. Look at CDXC as a prime example in the medical field. PGLC, PPRTF are also good examples that are outside the medical field. They may tie together in various forms and fashions, but a buyout is not imminent.
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Longer Than Most
2年前
MWM
11年前
dshade
11年前
Wildbilly
11年前
ZLAZARUS
12年前
